MMC logo

Marsh & McLennan

MMCNYSE
US Equity
$182.70 $2.89 (1.58%)
Live
1h
24h▼ 1.6%
7d▲ 0.1%
14d▲ 0.1%
30d▲ 0.1%
1y▼ 12.7%
🏦Market Cap
$349B
Large Cap
📈Revenue Growth (YoY)
+33.1%
High Growth
📊Gross Margin
66.2%
High
💵FCF Margin
15.6%
Healthy
⚖️P/S Ratio
10.0x
Elevated
Otter Score
48
Weak
MMC logo

Marsh & McLennan

MMC
Analyst Ratings
Price
$182.70
Total
26
Raised
3
Lowered
6
Avg PT
$199.40
H / L
$257 / $135
Institution
Cantor Fitzgerald
Reiterated · Overweight · 2026-01-14
$208.00
+13.80%
Wells Fargo
Reiterated · Equal Weight · 2026-01-13
$199.00
+8.90%
Barclays
Reiterated · Overweight · 2026-01-08
$210.00
+14.90%
Evercore ISI Group
Reiterated · Outperform · 2026-01-07
JP Morgan
Reiterated · Overweight · 2026-01-07
$163.00
−10.80%
Keefe, Bruyette & Woods
Reiterated · Market Perform · 2026-01-06
Citigroup
Reiterated · Neutral · 2025-12-04
$190.00
+4.00%
B of A Securities
Downgraded · Neutral → Underperform · 2025-11-03
TD Cowen
Reiterated · Hold · 2025-11-03
Goldman Sachs
Upgraded · Sell → Neutral · 2025-10-20
$199.00
+8.90%
UBS
Reiterated · Buy · 2025-10-08
$257.00
+40.70%
Morgan Stanley
Reiterated · Equal Weight · 2025-10-07
$190.00
+4.00%
Jefferies
Reiterated · Hold · 2025-04-11
$178.00
−2.60%
Raymond James
Reiterated · Outperform · 2025-02-06
$180.00
−1.50%
RBC Capital
Upgraded · Sector Perform → Outperform · 2024-12-12
$200.00
+9.50%
BMO Capital
Reiterated · Market Perform · 2024-10-22
$228.00
+24.80%
Roth MKM
Reiterated · Neutral · 2024-10-18
Piper Sandler
Downgraded · Overweight → Neutral · 2024-04-17
$211.00
+15.50%
Credit Suisse
Reiterated · Neutral · 2023-01-30
$157.00
−14.10%
Atlantic Equities
Downgraded · Overweight → Neutral · 2022-11-08
$185.00
+1.30%
MKM Partners
Reiterated · Neutral · 2020-05-01
CFRA
Upgraded · Hold → Buy · 2020-04-30
Deutsche Bank
Downgraded · Buy → Hold · 2017-10-04
$135.00
−26.10%
Macquarie
Downgraded · Outperform → Neutral · 2014-09-25
Nomura
Reiterated · Neutral · 2014-03-12
Miller Tabak
Downgraded · Buy → Hold · 2013-10-04
One row per institution · price target from the firm's latest published target